Kwarlay.com

Navigating the News Maze with Clarity

    • Medicine

    IMU-856 Shows Promise in Celiac Disease: Histologic Protection and Nutrient Absorption Key to Advancing Trials

    admin Posted on

    Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

    LEAVE A RESPONSE

    Your email address will not be published. Required fields are marked *

    admin
    View all posts

    You Might Also Like

    Slot
    TOGEL ONLINE